Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000868278-25-000011
Filing Date
2025-08-13
Accepted
2025-08-13 17:07:36
Documents
81
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q prph-20250630.htm   iXBRL 10-Q 1322398
2 EX-31.1 prph-2025630xexx311.htm EX-31.1 10800
3 EX-32.1 prph-2025630xexx321.htm EX-32.1 5212
  Complete submission text file 0000868278-25-000011.txt   9153652

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prph-20250630.xsd EX-101.SCH 70776
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT prph-20250630_cal.xml EX-101.CAL 131674
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT prph-20250630_def.xml EX-101.DEF 387894
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prph-20250630_lab.xml EX-101.LAB 911471
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prph-20250630_pre.xml EX-101.PRE 645164
84 EXTRACTED XBRL INSTANCE DOCUMENT prph-20250630_htm.xml XML 1176464
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-21617 | Film No.: 251212768
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)